Cand.scient. Ana Slipicevic - from Vivi Ann Flørenes's group at the Division of Pathology - will give her trial lecture on the subject "Dysregulation of apoptosis in cancer. An update" on Tuesday May 4th at 15.15.
She will defend her PhD thesis - entitled "Studies of the PI3K/Akt and MAPK/ERK1/2 signaling pathways: identification of novel downstream targets involved in development and progression of melanoma" at 10.15 on Wednesday May 5th.
Venue for both events: Auditorium (BU1), Radiumhospitalet, Montebello, Oslo
From major journals, first or last author from the Institute for Cancer Research
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Adv Drug Deliv Rev, 114326 (in press)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Nucleic Acids Res (in press)
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol (in press)